Pharmacology
DrugBankDescription
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Mechanism of Action
Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
Pharmacodynamics
Tranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.
Absorption
Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.
Toxicity
In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
Indication
For the treatment of major depressive episode without melancholia.
Half-life
1.5-3.2 hours in patients with normal renal and hepatic function
Effect Profile
Curated + 2 ReportsModerate stimulation, euphoria, and anxiety/jitters
Tolerance & Pharmacokinetics
drugs.wikiExperience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Real-World Dose Distribution
62K DosesFrom 5 individual dose entries
Form / Preparation
Most common forms and preparations reported
Harm Reduction
drugs.wikiIrreversible MAOI: although the parent drug’s plasma half-life is ~1.5–3.2 hours, enzyme inhibition persists until new MAO is synthesized, so interaction risks remain for at least 14 days after stopping (and often 10–21 days). Maintain a 14‑day washout when switching to or from serotonergic antidepressants; extend to 5 weeks after fluoxetine due to its long half-life. Hypertensive crisis (“cheese reaction”) can occur from dietary tyramine or sympathomimetic drugs; earliest sign is often a severe occipital headache, and can progress to chest pain, palpitations, shortness of breath, confusion, and seizures — seek emergency care immediately. Serotonin syndrome risk is high if combined with serotonergic medicines (e.g., SSRIs/SNRIs, clomipramine, MDMA, tramadol, DXM, linezolid, methylene blue); symptoms include agitation, hyperreflexia, clonus, fever, diaphoresis, diarrhea — urgent evaluation is required. Avoid OTC cold/cough products that contain dextromethorphan or decongestants (pseudoephedrine, phenylephrine); many carry a label warning against use within 14 days of an MAOI. Follow a low‑tyramine diet throughout therapy and for 2 weeks after stopping; avoid aged cheeses, cured/fermented meats, soy sauce/miso/yeast extracts, fava beans, and tap/draft beers; packaged spirits in modest amounts still require caution for hypotension/CNS effects. For planned surgery or dental procedures, inform anesthesia providers; some agents (e.g., meperidine, serotonergic antiemetics) are contraindicated, and perioperative plans may need adjustment. Tranylcypromine has a stimulant-like profile and can cause insomnia and orthostatic hypotension; dosing earlier in the day and dividing doses may reduce insomnia and BP swings. Rare hepatotoxicity has been reported; baseline and periodic liver function and blood pressure monitoring are prudent in clinical use. Carry an MAOI alert card/bracelet listing key contraindications (meperidine, DXM, serotonergic antidepressants, sympathomimetics) so emergency staff can avoid dangerous drugs.
References
Drugs.wiki References
- StatPearls: Tranylcypromine (updated Jan 19, 2025) – dosing, contraindications, diet, washout windows, hypertensive crisis & serotonin syndrome
- DrugBank DB00752 – pharmacokinetics and food interactions (tyramine foods, alcohol caution)
- StatPearls: MAO Inhibitors – adverse effects (cheese reaction), serotonergic toxicity overview
- StatPearls: Dextromethorphan Toxicity – serotonin syndrome risk with MAOIs/DXM
- TripSit Wiki/Combination resources – MAOI combinations cautionary context
- Bluelight: List of Dangerous & Potentially Unsafe Combinations – community HR consensus on MAOIs with serotonergic/stimulant agents
- Drugs-Forum Wiki: Monoamine Oxidase Inhibitors – hypertensive crisis & serotonin syndrome explanations